PEOPLE - Baxter International makes appointment:
This article was originally published in Clinica
Baxter International has appointed Wayne Hockmeyer to its board of directors, effective next month. The Deerfield, Illinois firm aims to harness Dr Hockmeyer's "extensive scientific and R&D expertise", which features the founding of MedImmune (recently acquired by AstraZeneca), to help achieve its innovation and growth objectives, said chairman and CEO Robert Parkinson.
You may also be interested in...
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.
A flurry of US biosimilar launches over the past few months has opened several molecules to true, multi-source competition, with a range of pricing strategies seen from competitors. However, some brands that already face biosimilar competition elsewhere in the world are still poised to enjoy a significant period of exclusivity in the US, such as AbbVie’s Humira.
It is the question that continues to exercise the minds of management boards in the medtech industry even as digital health care tools become increasingly ingrained in commercial R&D and operations – and in patient treatment pathways.